Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-adapted selinexor plus standard therapy for newly diagnosed multiple myeloma undergoing autologous stem cell transplant
ACTRN12622001366741Phase 2Recruiting
- Sponsor
- Australasian Myeloma Research Consortium
- Start
- May 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of selinexor, bortezomib, lenalidomide, dexamethasone and melphalan in multiple myeloma (MM) (4 arms), sponsored by Australasian Myeloma Research Consortium. Primary endpoint: Efficacy of adding selinexor in high-risk newly diagnosed multiple myeloma. Started May 2023; status: recruiting.
02
Drugs
selinexorbortezomiblenalidomidedexamethasonemelphalan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12622001366741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622001366741.